22393359|t|Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles.
22393359|a|This study investigated the impact of chronic exposure to continuous (CoP4) versus cyclic progesterone (CyP4) alone or in combination with 17beta-estradiol (E2) on gene expression profiles targeting bioenergetics, metabolism and inflammation in the adult female rat hippocampus. High-throughput qRT-PCR analyses revealed that ovarian hormonal depletion induced by ovariectomy (OVX) led to multiple significant gene expression alterations, which were to a great extent reversed by co-administration of E2 and CyP4. In contrast, co-administration of E2 and CoP4 induced a pattern highly resembling OVX. Bioinformatics analyses further revealed clear disparities in functional profiles associated with E2+CoP4 and E2+CyP4. Genes involved in mitochondrial energy (ATP synthase alpha subunit; Atp5a1), redox homeostasis (peroxiredoxin 5; Prdx5), insulin signaling (insulin-like growth factor I; Igf1), and cholesterol trafficking (liver X receptor alpha subtype; Nr1h3), differed in direction of regulation by E2+CoP4 (down-regulation relative to OVX) and E2+CyP4 (up-regulation relative to OVX). In contrast, genes involved in amyloid metabolism (beta-secretase; Bace1) differed only in degree of regulation, as both E2+CoP4 and E2+CyP4 induced down-regulation at different efficacy. E2+CyP4-induced changes could be associated with regulation of progesterone receptor membrane component 1(Pgrmc1). In summary, results from this study provide evidence at the molecular level that differing regimens of hormone therapy (HT) can induce disparate gene expression profiles in brain. From a translational perspective, confirmation of these results in a model of natural menopause, would imply that the common regimen of continuous combined HT may have adverse consequences whereas a cyclic combined regimen, which is more physiological, could be an effective strategy to maintain neurological health and function throughout menopausal aging.
22393359	25	37	progesterone	Chemical	MESH:D011374
22393359	195	199	CoP4	Chemical	-
22393359	215	227	progesterone	Chemical	MESH:D011374
22393359	229	233	CyP4	Chemical	-
22393359	264	280	17beta-estradiol	Chemical	MESH:D004958
22393359	282	284	E2	Chemical	MESH:D004958
22393359	354	366	inflammation	Disease	MESH:D007249
22393359	387	390	rat	Species	10116
22393359	489	500	ovariectomy	Disease	
22393359	502	505	OVX	Disease	
22393359	626	628	E2	Chemical	MESH:D004958
22393359	673	675	E2	Chemical	MESH:D004958
22393359	680	684	CoP4	Chemical	-
22393359	721	724	OVX	Disease	
22393359	913	919	Atp5a1	Gene	65262
22393359	941	956	peroxiredoxin 5	Gene	113898
22393359	958	963	Prdx5	Gene	113898
22393359	985	1013	insulin-like growth factor I	Gene	24482
22393359	1015	1019	Igf1	Gene	24482
22393359	1026	1037	cholesterol	Chemical	MESH:D002784
22393359	1083	1088	Nr1h3	Gene	58852
22393359	1130	1132	E2	Chemical	MESH:D004958
22393359	1167	1170	OVX	Disease	
22393359	1176	1178	E2	Chemical	MESH:D004958
22393359	1179	1183	CyP4	Chemical	-
22393359	1211	1214	OVX	Disease	
22393359	1248	1255	amyloid	Disease	MESH:C000718787
22393359	1284	1289	Bace1	Gene	29392
22393359	1338	1340	E2	Chemical	MESH:D004958
22393359	1341	1345	CoP4	Chemical	-
22393359	1350	1352	E2	Chemical	MESH:D004958
22393359	1353	1357	CyP4	Chemical	-
22393359	1405	1407	E2	Chemical	MESH:D004958
22393359	1408	1412	CyP4	Chemical	-
22393359	1468	1510	progesterone receptor membrane component 1	Gene	291948
22393359	1511	1517	Pgrmc1	Gene	291948
22393359	Association	MESH:D004958	24482
22393359	Association	MESH:C000718787	29392
22393359	Association	MESH:D004958	291948
22393359	Association	MESH:D004958	113898

